Carbon nanotube exposure sensitize human ovarian cancer cells to paclitaxel

Journal of Nanoscience and Nanotechnology

Volumn 12, Issue 9, 2012, Pages 7211-7214

  Zhang, Wenjing ^a   Zhang, Daoqiang ^b   Tan, Jianhua ^b   Cong, Haibo ^b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b WEIFANG MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Chemosensitivity; Ovarian Cancer; Sensitization; SWCNTs

Indexed keywords

ANTICANCER DRUG; BIOMEDICAL FIELDS; CHEMOSENSITIVITY; CHEMOTHERAPEUTIC DRUGS; OVARIAN CANCER CELLS; OVARIAN CANCERS; PACLITAXEL; POTENTIAL APPLICATIONS; SENSITIZATION; SWCNTS;

CARBON NANOTUBES; DISEASES; DRUG DELIVERY;

CELL DEATH;

ANTINEOPLASTIC AGENT; CARBON NANOTUBE; PACLITAXEL;

ARTICLE; FEMALE; HUMAN; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; FEMALE; HUMANS; NANOTUBES, CARBON; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 84866065799     PISSN: 15334880     EISSN: 15334899     Source Type: Journal    
DOI: 10.1166/jnn.2012.6506     Document Type: Article

References (21)

1. P. D. Marcato and N. Duran, J. Nanosci. Nanotechnol. 8, 2216 (2008).
2. S. Singh, J. Nanosci. Nanotechnol. 10, 7906 (2010).
3. A. M. Elhissi, W. Ahmed, I. U. Hassan, V. R. Dhanak, and A. D'Emanuele, J. Drug. Deliv. 2012, 837327 (2012).
4. P. Zahedi, R. Yoganathan, M. Piquette-Miller, and C. Allen, Expert Opin. Drug. Deliv. 9, 567 (2012).
5. M. Comamala, M. Pinard, C. Theriault, I. Matte, A. Albert, M. Boivin, J. Beaudin, A. Piche, and C. Rancourt, Br. J. Cancer 104, 989 (2011).
6. V. L. Galic, T. J. Herzog, J. D. Wright, and S. N. Lewin, Expert Opin. Investig. Drugs 20, 813 (2011).
7. Z. He, J. Gao, Q. Wang, M. Liu, Y. Li, X. Li, H. Tang, and J. Zheng, Oncol. Rep. 20, 325 (2008).
8. Q. Wang, Z. He, J. Gao, S. Hu, M. Huang, M. Liu, J. Zheng, and H. Tang, Cancer Lett. 272, 277 (2008).
9. D. Pantarotto, J. P. Briand, M. Prato, and A. Bianco, Chem. Commun. (Camb) 1, 16 (2004).
10. A. Bianco, K. Kostarelos, and M. Prato, Curr. Opin. Chem. Biol. 9, 674 (2005).
11. A. Tan, L. Yildirimer, J. Rajadas, H. De La Pena, G. Pastorin, and A. Seifalian, Nanomedicine (Lond) 6, 1101 (2011).
12. H. C. Huang, S. Barua, G. Sharma, S. K. Dey, and K. Rege, J. Control Release 155, 344 (2011).
13. V. S. Thakare, M. Das, A. K. Jain, S. Patil, and S. Jain, Nanomedicine 5, 1277 (2010).
14. R. Singh and H. S. Nalwa, J. Biomed. Nanotechnol. 7, 489 (2011).
15. C. Dumontet, G. E. Duran, K. A. Steger, L. Beketic-Oreskovic, and B. I. Sikic, Cancer Res. 56, 1091 (1996).
16. A. M. Casazza and C. R. Fairchild, Cancer Treat. Res. 87, 149 (1996).
17. X. Chen, A. Kis, A. Zettl, and C. R. Bertozzi, Proc. Natl. Acad. Sci. USA 104, 8218 (2007).
18. A. A. Bhirde, V. Patel, J. Gavard, G. Zhang, A. A. Sousa, A. Masedunskas, R. D. Leapman, R. Weigert, J. S. Gutkind, and J. F. Rusling, ACS Nano 3, 307 (2009).
19. N. W. Kam, M. O'Connell, J. A. Wisdom, and H. Dai, Proc. Natl. Acad. Sci. USA 102, 11600 (2005).
20. J. Hone and L. Kam, Nat. Nanotechnol. 2, 140 (2007).
21. C. Klumpp, K. Kostarelos, M. Prato, and A. Bianco, Biochim. Biophys. Acta 1758, 404 (2006).